Two Sigma Investments LP Sells 43,923 Shares of Ocugen, Inc. (NASDAQ:OCGN)

Two Sigma Investments LP decreased its position in shares of Ocugen, Inc. (NASDAQ:OCGN) by 12.1% during the 4th quarter, Holdings Channel reports. The fund owned 319,795 shares of the company’s stock after selling 43,923 shares during the quarter. Two Sigma Investments LP’s holdings in Ocugen were worth $257,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in Ocugen during the 4th quarter worth approximately $30,000. Ameriprise Financial Inc. bought a new position in Ocugen during the 4th quarter worth approximately $30,000. Virtu Financial LLC bought a new position in Ocugen during the 4th quarter worth approximately $32,000. Tower Research Capital LLC TRC boosted its stake in Ocugen by 309.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company’s stock worth $32,000 after acquiring an additional 30,120 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in Ocugen during the 4th quarter worth approximately $40,000. Institutional investors own 10.27% of the company’s stock.

Ocugen Stock Performance

Shares of OCGN stock opened at $1.16 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. The company has a market capitalization of $338.76 million, a P/E ratio of -6.44 and a beta of 4.20. The company’s 50 day moving average price is $0.78 and its two-hundred day moving average price is $0.75. Ocugen, Inc. has a 52 week low of $0.52 and a 52 week high of $1.98.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Friday, May 9th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. The firm had revenue of $1.48 million for the quarter. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. On average, analysts expect that Ocugen, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OCGN has been the topic of several recent analyst reports. Chardan Capital reissued a “buy” rating and set a $7.00 price objective on shares of Ocugen in a research note on Monday, May 12th. HC Wainwright reduced their price objective on shares of Ocugen from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, May 12th.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.